Paloma Partners’s Privia Health PRVA Stock Holding History

Paloma Partners’s Portfolio PRVA Stock Details PRVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-9,711	Closed	-$260K	–	1623
2022 Q1	$260K	Sell	9,711 -6,034	-38%	-$142K	0.01%	1239
2021 Q4	$407K	Buy	+15,745	New	+$392K	0.01%	1221

Other funds holding PRVA

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

SIG

Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Paloma Partners's PRVA Position: Q2 2022 in Review

Paloma Partners sold out of Privia Health (PRVA) in Q2 2022, closing a stake of 9,711 shares — an estimated $260K sold.

Paloma Partners first reported a position in PRVA in Q4 2021 and held it in 2 quarters. The position peaked at $407K in Q4 2021. 151 funds tracked by Wall St. Rank hold PRVA as of Q2 2022.

Paloma Partners reported no remaining Privia Health position as of Q2 2022 after selling out during the quarter.
Paloma Partners sold 9,711 Privia Health shares in Q2 2022, an estimated $260K.
Paloma Partners first reported a position in Privia Health in Q4 2021 and held it in 2 quarters.
Paloma Partners's Privia Health position peaked at $407K in Q4 2021.
151 funds tracked by Wall St. Rank held Privia Health as of Q2 2022.

Based on Paloma Partners's 13F filing for Q2 2022, filed 15 Aug 2022.